<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185679</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-12600</org_study_id>
    <secondary_id>BMT123</secondary_id>
    <secondary_id>NCI-2011-00424</secondary_id>
    <secondary_id>77453</secondary_id>
    <nct_id>NCT00185679</nct_id>
  </id_info>
  <brief_title>Haploid Allogeneic Transplant Using the CliniMACS System</brief_title>
  <official_title>A Feasibility Study Evaluating Haploidentical Allogeneic Transplantation Using the CliniMACS System in Patients With Advanced Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ginna Laport</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the proportion of patients with donor neutrophil engraftment within 30 days of&#xD;
      allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after&#xD;
      transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the proportion of patients with donor neutrophil engraftment within 30 days of&#xD;
      allogeneic transplant; assess the incidence of acute GvHD during the first 100 days after&#xD;
      transplantation; and assess platelet engraftment, graft failure, chronic GvHD, clinical&#xD;
      safety, and devise performance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was superseded by the subsequent study IRB-15919 (NCT01050764)&#xD;
  </why_stopped>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutrophil Engraftment</measure>
    <time_frame>30 days post-transplant</time_frame>
    <description>Number of subjects recovering neutrophils, assessed as 1st of 3 consecutive days on which ANC &gt; 0.5x10e9/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute GvHD (Grade II-IV)</measure>
    <time_frame>within 100 days post-transplant</time_frame>
    <description>Number of subjects with acute GvHD (grade II-IV) within 100 days post-transplant, per the Consensus Conference on Acute GvHD Grading (Przepiorka D, et al. Bone Marrow Transplantation. 1995. 15:825-828).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Recovery</measure>
    <time_frame>40 days</time_frame>
    <description>Number of subjects recovering platelets to &gt; 20x10e9/L, assessed on the 7th day unsupported by platelet transfusions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors</condition>
  <condition>Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase</condition>
  <condition>Myelodysplastic Syndrome (MDS) - High and Intermediate Risk</condition>
  <condition>Non-Hodgkin's Lymphoma (NHL)</condition>
  <condition>Chronic Lymphocytic Leukemia (CLL) - Refractory</condition>
  <arm_group>
    <arm_group_label>Haploidentical Allogeneic Transplant Using CliniMACS System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CliniMACS System</intervention_name>
    <description>The CliniMACS System is a cell selection device consisting of the following components:&#xD;
Computer-controlled instrument;&#xD;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)&#xD;
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)&#xD;
Wash buffer</description>
    <arm_group_label>Haploidentical Allogeneic Transplant Using CliniMACS System</arm_group_label>
    <other_name>CliniMACS Cell Selection System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        RECIPIENT INCLUSION CRITERIA&#xD;
&#xD;
        Histopathologically-confirmed diagnosis of hematological or lymphatic malignancy, defined&#xD;
        as one of the following:&#xD;
&#xD;
          -  Acute myeloid leukemia (AML) as primary refractory disease, or in relapse&#xD;
&#xD;
          -  Acute leukemia in first remission with poor risk factors and molecular prognosis&#xD;
&#xD;
          -  AML with -5,-7, t(6;9), tri8, -11&#xD;
&#xD;
          -  Acute lymphocytic / lymphoblastic leukemia (ALL) with Phil+ t(9;22),(q34;q11.2), and&#xD;
             t(4:11)(q21;23)&#xD;
&#xD;
          -  Chronic myelogenous leukemia (CML in accelerated, second chronic phase&#xD;
&#xD;
          -  Myelodysplastic syndrome with high intermediate to high risk categories&#xD;
&#xD;
          -  Non-Hodgkin's lymphoma (NHL)&#xD;
&#xD;
          -  Chronic lymphocytic leukemia (CLL), Refractory &lt; 50 years old at time of registration&#xD;
             Donor is related Donor is genotypically-matched and haploidentical for HLA-A, B,C and&#xD;
             DRB1, DQ loci Donor differs for 2 or 3 HLA alleles on the unshared haplotype in the&#xD;
             GvHD direction No HLA-matched sibling or matched unrelated donor is identified ECOG&#xD;
             performance status not more than 2 LVEF &gt; 45% DLCO &gt; 50% corrected for hemoglobin&#xD;
             Serum creatinine&#xD;
&#xD;
          -  &lt; 1.5 mg/dL OR&#xD;
&#xD;
          -  creatinine clearance &gt; 50 mL/min for those above serum creatinine of 1.5 mg/dL serum&#xD;
             bilirubin &lt; 2.0 mg/dL ALT &lt; 2x ULN (unless secondary to disease) Females of&#xD;
             childbearing potential must have a negative serum or urine beta-HCG test within 3&#xD;
             weeks of registration No prior cancer within 5 years with the exception of&#xD;
             surgically-cured, non-melanoma skin cancer or in situ cancer of the cervix No prior&#xD;
             myeloablative therapy or transplant Duly-executed informed consent&#xD;
&#xD;
        RECIPIENT EXCLUSION CRITERIA Suitable candidate for autologous transplantation&#xD;
        Participation in other investigational drugs or devices trials that might influence the&#xD;
        study endpoints Evidence of active hepatitis Evidence of active cirrhosis HIV-positive&#xD;
        History of invasive aspergillosis Presence of any other uncontrolled, active infection, ie,&#xD;
        bacterial, viral or fungal Uncontrolled CNS involvement Documented allergy to murine&#xD;
        proteins Documented allergy to iron dextran Lactating female Female of child-bearing&#xD;
        potential unwilling to implement adequate birth control Medical problem /&#xD;
        neurologic/psychiatric dysfunction which would impair his/her ability to be compliant with&#xD;
        the medical regimen and/or to tolerate transplantation, in the opinion of the principal&#xD;
        investigator Medical problem / neurologic/psychiatric dysfunction which would prolong&#xD;
        hematologic recovery and place the recipient at unacceptable risk, in the opinion of the&#xD;
        principal investigator would .&#xD;
&#xD;
        DONOR INCLUSION CRITERIA Age &lt; 60 years Weight &gt; 25 kg Medical history and physical&#xD;
        examination confirm good health status as defined by institutional standards Within 30 days&#xD;
        of apheresis collection, seronegative for HIV assessed as HIV Ag; HIV 1+2 Ab; or HTLV I/II&#xD;
        Ab Within 30 days of apheresis collection, seronegative for hepatitis assessed as HBsAg;&#xD;
        HBcAb (IgM and IgG); or HCV Ab Within 30 days of apheresis collection, seronegative for&#xD;
        syphilis assessed as RPR Genotypically haploidentical as determined by HLA typing Female&#xD;
        donors of child-bearing potential must have a negative serum or urine beta-HCG test within&#xD;
        3 weeks of mobilization Capable of undergoing leukapheresis Has adequate venous access&#xD;
        Willing to undergo insertion of a central catheter should leukapheresis via peripheral vein&#xD;
        be inadequate Agreeable to second donation of PBPC (or a bone marrow harvest) should the&#xD;
        recipient fail to demonstrate sustained engraftment following the transplant Duly-executed&#xD;
        informed consent Screened for CMV seroreactivity&#xD;
&#xD;
          -  Must be seronegative donor if recipeint is seronegative.&#xD;
&#xD;
          -  Otherwise the donor will be selected on the ability of NK cell alloreactivity based&#xD;
             upon HLA typing results and donors who are capable of NK cell alloreactivity will be&#xD;
             used preferentially.&#xD;
&#xD;
        DONOR EXCLUSION CRITERIA Evidence of active infection (including urinary tract infection,&#xD;
        or upper respiratory tract infection) Evidence of hepatitis (on screening) Medical,&#xD;
        physical or psychological reason which makes the donor unlikely to tolerate or cooperate&#xD;
        with growth factor therapy and leukapheresis Factors placing donor at increased risk for&#xD;
        leukapheresis or G-CSF-related complications Lactating female Female of child-bearing&#xD;
        potential unwilling to implement adequate birth control HIV-positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ginna G Laport, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>February 26, 2015</results_first_submitted>
  <results_first_submitted_qc>February 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 9, 2015</results_first_posted>
  <last_update_submitted>February 26, 2015</last_update_submitted>
  <last_update_submitted_qc>February 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Ginna Laport</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Haploidentical Allogeneic Transplant Using CliniMACS System</title>
          <description>The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.&#xD;
CliniMACS System: The CliniMACS System is a cell selection device consisting of the following components:&#xD;
Computer-controlled instrument;&#xD;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)&#xD;
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)&#xD;
Wash buffer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Haploidentical Allogeneic Transplant Using CliniMACS System</title>
          <description>The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.&#xD;
The CliniMACS System is a cell selection device consisting of the following components:&#xD;
Computer-controlled instrument;&#xD;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)&#xD;
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)&#xD;
Wash buffer</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" lower_limit="21" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Neutrophil Engraftment</title>
        <description>Number of subjects recovering neutrophils, assessed as 1st of 3 consecutive days on which ANC &gt; 0.5x10e9/L</description>
        <time_frame>30 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Allogeneic Transplant Using CliniMACS System</title>
            <description>The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.&#xD;
CliniMACS System: The CliniMACS System is a cell selection device consisting of the following components:&#xD;
Computer-controlled instrument;&#xD;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)&#xD;
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)&#xD;
Wash buffer</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophil Engraftment</title>
          <description>Number of subjects recovering neutrophils, assessed as 1st of 3 consecutive days on which ANC &gt; 0.5x10e9/L</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute GvHD (Grade II-IV)</title>
        <description>Number of subjects with acute GvHD (grade II-IV) within 100 days post-transplant, per the Consensus Conference on Acute GvHD Grading (Przepiorka D, et al. Bone Marrow Transplantation. 1995. 15:825-828).</description>
        <time_frame>within 100 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Allogeneic Transplant Using CliniMACS System</title>
            <description>The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.&#xD;
CliniMACS System: The CliniMACS System is a cell selection device consisting of the following components:&#xD;
Computer-controlled instrument;&#xD;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)&#xD;
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)&#xD;
Wash buffer</description>
          </group>
        </group_list>
        <measure>
          <title>Acute GvHD (Grade II-IV)</title>
          <description>Number of subjects with acute GvHD (grade II-IV) within 100 days post-transplant, per the Consensus Conference on Acute GvHD Grading (Przepiorka D, et al. Bone Marrow Transplantation. 1995. 15:825-828).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Recovery</title>
        <description>Number of subjects recovering platelets to &gt; 20x10e9/L, assessed on the 7th day unsupported by platelet transfusions</description>
        <time_frame>40 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haploidentical Allogeneic Transplant Using CliniMACS System</title>
            <description>The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.&#xD;
CliniMACS System: The CliniMACS System is a cell selection device consisting of the following components:&#xD;
Computer-controlled instrument;&#xD;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)&#xD;
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)&#xD;
Wash buffer</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Recovery</title>
          <description>Number of subjects recovering platelets to &gt; 20x10e9/L, assessed on the 7th day unsupported by platelet transfusions</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs reported through Day 100 post-transplant.</time_frame>
      <desc>Non-serious adverse events not reported</desc>
      <group_list>
        <group group_id="E1">
          <title>Haploidentical Allogeneic Transplant Using CliniMACS System</title>
          <description>The CliniMACS cell selection system (Miltenyi Biotec) will be used to enrich hematopoietic stem cells from related, haploidentical, HLA-matched donors, who matched on the A,B,C and DRB1, DQ loci.&#xD;
CliniMACS System: The CliniMACS System is a cell selection device consisting of the following components:&#xD;
Computer-controlled instrument;&#xD;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)&#xD;
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)&#xD;
Wash buffer</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS - Other, graft failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, demyelinating ecephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Treatment-related secondary malignancy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, pulmonary fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ginna G Laport, MD</name_or_title>
      <organization>Stanford Cancer Institute</organization>
      <phone>650-723-8222 ext 13911</phone>
      <email>ginna.laport@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

